EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY-NC 4.0

Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome

Marie Beylot-Barry iD, Nina Booken, Carsten Weishaupt iD, Julia Scarisbrick, Wende Wu, Jan-Paul Rosen, Michael C Medley iD

Journal of the European Academy of Dermatology and Venereology · 2023-02 · 37 (2) · 311-316

DOI: 10.1111/jdv.18549 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 30.08.2022. Verfasst von Marie Beylot-Barry und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Bordeaux, UMR 1312 INSERM, Bordeaux, France. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Sezary Syndrome, Skin Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Kyowa Kirin, Kyowa Hakko Kirin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cutaneous T‐cell lymphomas (CTCL) are rare types of non‐Hodgkin lymphoma, which present in skin. Mycosis fungoides (MF) and Sézary syndrome (SS) are subtypes which make up two‐thirds of all CTCL cases. The phase 3 MAVORIC study (NCT01728805) compared mogamulizumab to vorinostat in MF and SS patients, with post hoc data showing a trend for higher efficacy in mogamulizumab‐treated patients as baseline blood tumour burden increases.

Objectives

The aim of this study was to use updated post hoc analyses in order to examine the efficacy of mogamulizumab and vorinostat in MF patients when stratified by baseline blood involvement and to determine what factors affect time‐to‐global and time‐to‐skin response to inform clinical follow‐up.

Methods

Post hoc analyses were carried out using data from MAVORIC. Overall response rate (ORR), progression‐free survival (PFS) and time‐to‐next‐treatment (TTNT) data were used to assess efficacy in patients with MF. Time‐to‐global response (TTR) was examined by disease subtype, by blood involvement in MF patients, and time‐to‐skin response was examined by blood involvement in MF patients.

Results

Numerically superior results were seen for ORR, PFS and TTNT in mogamulizumab‐treated patients with MF compared with vorinostat, with a trend for outcomes improving with increasing baseline blood class. Statistically significant results for mogamulizumab compared with vorinostat were seen for MF B1 pts for PFS (8.43 vs. 2.83 months, p = 0.003) and TTNT (11.9 vs. 3.13 months, p = 0.002), and for MF B2 pts for ORR (46.2 vs. 9.1 months, p = 0.033).

Conclusions

In mogamulizumab‐treated MF patients, ORR and PFS were seen to improve with increasing blood involvement, which led to improved TTNT. TTR was more predictable for mogamulizumab‐treated MF patients with blood involvement, and skin response may take longer than previously reported in some patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, T-Cell, CutaneousMycosis FungoidesSezary SyndromeSkin NeoplasmsHumansVorinostatAntibodies, Monoclonal, Humanized

Substanzen

VorinostatmogamulizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • University of Bordeaux, UMR 1312 INSERM, Bordeaux, France.
  • Dermatology Department, CHU Bordeaux, Bordeaux, France.
  • Department of Dermatology and Venereology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Dermatology, University Hospital of Muenster, Muenster, Germany.
  • University Hospital Birmingham, Birmingham, UK.
  • Kyowa Kirin, Inc, Princeton, New Jersey, USA.

ORCID-Profile: Marie Beylot-Barry, Carsten Weishaupt, Michael C Medley

Förderung

  • Kyowa Kirin
  • Kyowa Hakko Kirin

Zitieren

APA

Beylot-Barry, M., Booken, N., Weishaupt, C., Scarisbrick, J., Wu, W., Rosen, J. P., & Medley, M. C. (2023). Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome. Journal of the European Academy of Dermatology and Venereology, 37(2), 311-316. https://doi.org/10.1111/jdv.18549

Vancouver

Beylot-Barry M, Booken N, Weishaupt C, Scarisbrick J, Wu W, Rosen JP, et al. Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome. Journal of the European Academy of Dermatology and Venereology. 2023;37(2):311-316. doi:10.1111/jdv.18549

BibTeX
@article{BeylotBarry2023,
  author = {Beylot-Barry, Marie and Booken, Nina and Weishaupt, Carsten and Scarisbrick, Julia and Wu, Wende and Rosen, Jan-Paul and Medley, Michael C},
  title = {Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2023},
  volume = {37},
  number = {2},
  pages = {311--316},
  doi = {10.1111/jdv.18549}
}
Kostenlos starten →